Liver Int: The correlation between aspirin and statins and the risk of liver cancer in patients with chronic hepatitis B

Aspirin and statins have been recommended for the prevention of hepatocellular carcinoma (HCC)
.

However, the combined effect of aspirin and statins on the risk of HCC in patients with chronic hepatitis B (CHB) remains unclear

prevention

This is a nationwide nested case-control study using National Health Insurance Service data collected in South Korea from 2005 to 2015
.

In a cohort of 538,135 newly-treated, non-cirrhotic CHB patients, 6539 HCC patients were matched with 26156 controls, and conditional logistic regression analysis was performed

Correlation between statin and aspirin exposure and cumulative risk of HCC

Correlation between statin and aspirin exposure and cumulative risk of HCC

In this nested case-control study, statins and aspirin were significantly associated with a reduction in HCC risk (odds ratio [OR] were 0.
34, 95%CI 0.
32-0.
37 and 0.
92, 95%CI 0.
85-0.
99, respectively)
.

However, only a dose-dependent risk reduction was observed in statins

Statins and aspirin are significantly associated with a reduction in HCC risk.

Correlation between statin ± aspirin exposure and cumulative risk of HCC

Correlation between statin ± aspirin exposure and cumulative risk of HCC

Sensitivity analysis in the historical cohort showed that statin users (n=244455; HR 0.
67; 95%CI 0.
66-0.
68) and aspirin users (n=288777; HR 0.
81; 95%CI 0.
80-0.
82) had HCC risk Both are significantly reduced
.

In the drug stratification analysis, whether or not aspirin was taken, statins were associated with a significant reduction in the risk of HCC, but aspirin did not show this correlation

Both statin users (n=244455; HR 0.

Original source:

Original source:

Choi Won-Mook,Kim Hyo Jeong,Jo Ae Jeong et al.

Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: a nationwide population-based study in this message